Ura N, Shimamoto K, Tanaka S, Nishimiya T, Mita T, Nakagawa M, Maeda T, Yamaguchi Y, Iimura O
J Clin Hypertens. 1985 Mar;1(1):15-22.
To further clarify the role of the renal kallikrein-kinin system in essential hypertension, a sensitive and simple method for the determination of both human urinary kininase I and kininase II was established, and the system components were determined in patients. In the measurement of kininase activity, desalted urine samples were incubated with synthetic bradykinin, and the reaction was terminated with kininase inhibitors, ethylene diamine tetraacetic acid and phenanthroline. Thus, kininase activity was determined as the kinin-destroying capacity. Moreover, the specific inhibitor for kininase II, SQ14225, was applied for the separation of kininase I and kininase II activities. Daily urinary excretions of total kininase and kininase I activities were significantly higher in essential hypertensive patients than those in normotensive subjects, whereas no difference was observed in kininase II activity. As reported previously, daily excretions of urinary kallikrein and kinin simultaneously determined in these patients were significantly lower than excretions in normotensive subjects. From these results, it was suggested that not only decreased renal kallikrein, but also increased kininase activity, may play an important role in the suppression of the renal kallikrein-kinin system through the reduction of active kinin level in essential hypertension.
为了进一步阐明肾脏激肽释放酶-激肽系统在原发性高血压中的作用,建立了一种灵敏且简便的测定人尿激肽酶I和激肽酶II的方法,并对患者的该系统组分进行了测定。在测定激肽酶活性时,将脱盐后的尿样与合成缓激肽一起孵育,然后用激肽酶抑制剂乙二胺四乙酸和邻菲罗啉终止反应。因此,激肽酶活性被测定为激肽破坏能力。此外,应用激肽酶II的特异性抑制剂SQ14225来分离激肽酶I和激肽酶II的活性。原发性高血压患者每日尿中总激肽酶和激肽酶I活性的排泄量显著高于血压正常者,而激肽酶II活性未观察到差异。如先前报道,在这些患者中同时测定的尿激肽释放酶和激肽的每日排泄量显著低于血压正常者。从这些结果推测,在原发性高血压中,不仅肾脏激肽释放酶减少,而且激肽酶活性增加,可能通过降低活性激肽水平在抑制肾脏激肽释放酶-激肽系统中起重要作用。